13F Pro

SEC Form 4 reporting owner

Iannone Robert

Iannone Robert has filed 18 Form 4 transactions reported between January 16, 2026 and August 27, 2026, as EVP, Global Head of R&D & CMO of Jazz Pharmaceuticals plc, Director of PLIANT THERAPEUTICS, INC. and Director of Autolus Therapeutics plc.

Name as filed: Iannone Robert

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$19.2M
6 lines
Companies
3
with Form 4 filings
Latest transaction
Aug 27, 2026
transaction date

Roles and reported holdings

  • JAZZJazz Pharmaceuticals plc
    Jan 16, 2026 – Aug 27, 2026

    EVP, Global Head of R&D & CMO

    Held directly65,686 sh as of Aug 27, 2026 · Form 4

    24 months: $19.2M sold

  • PLRXPLIANT THERAPEUTICS, INC.
    Jul 9, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • AUTLAutolus Therapeutics plc
    Jun 29, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 18 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Aug 27, 2026JAZZEVP, Global Head of R&D & CMOOpen-market saleCode S · direct300$76K@ $252.76Form 4
Aug 27, 2026JAZZEVP, Global Head of R&D & CMOOpen-market saleCode S · direct9,259$2.3M@ $251.95Form 4
Aug 27, 2026JAZZEVP, Global Head of R&D & CMOOpen-market saleCode S · direct19,639$4.9M@ $250.60Form 4
Aug 27, 2026JAZZEVP, Global Head of R&D & CMOOpen-market saleCode S · direct18,113$4.5M@ $250.02Form 4
Aug 27, 2026JAZZEVP, Global Head of R&D & CMOOpen-market saleCode S · direct11,423$2.8M@ $248.67Form 4
Aug 27, 2026JAZZEVP, Global Head of R&D & CMOOpen-market saleCode S · direct18,187$4.5M@ $247.86Form 4
Aug 27, 2026JAZZEVP, Global Head of R&D & CMOOption exerciseCode M · direct2,916$400K@ $137.12Form 4
Aug 27, 2026JAZZEVP, Global Head of R&D & CMOOption exerciseCode M · direct27,584$3.8M@ $137.12Form 4
Aug 27, 2026JAZZEVP, Global Head of R&D & CMOOption exerciseCode M · direct884$100K@ $113.10Form 4
Aug 27, 2026JAZZEVP, Global Head of R&D & CMOOption exerciseCode M · direct26,116$3.0M@ $113.10Form 4
Jul 9, 2026PLRXDirectorGrant or awardCode A · direct60,000—Form 4
Jun 30, 2026JAZZEVP, Global Head of R&D & CMOShares withheld for tax or exercise priceCode F · direct3,764$895K@ $237.72Form 4
Jun 29, 2026AUTLDirectorGrant or awardCode A · direct47,500—Form 4
Jun 29, 2026AUTLDirectorGrant or awardCode A · direct31,667—Form 4
Mar 5, 2026JAZZEVP, Global Head of R&D & CMOShares withheld for tax or exercise priceCode F · direct6,209$1.2M@ $188.69Form 4
Feb 26, 2026JAZZEVP, Global Head of R&D & CMOGrant or awardCode A · direct14,822—Form 4
Jan 16, 2026JAZZEVP, Global Head of R&D & CMOShares withheld for tax or exercise priceCode F · direct4,140$709K@ $171.16Form 4
Jan 16, 2026JAZZEVP, Global Head of R&D & CMOGrant or awardCode A · direct11,699—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.